By the time the characteristic features of PD such as bradykinesia, rigidity, postural instability, and resting tremor become obvious, approximately 60-70% of DA neurons in the SNpc are lost.
PD affects approximately 1–2% of the population, above the age of 55 and with the steady growth of the ageing population, disease management is a growing concern for neurologists and other physicians. Parkinson’s disease (PD), the second most common neurodegenerative disorder, is characterised by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) region of the brain. To maintain this neuroprotection, however, continuous Ubisol- Q 10 supplementation was required, if withdrawn, the neuronal death pathway resumed, suggesting that the presence of CoQ 10 was essential for blocking the pathway. The outcomes were evaluated based on the number of surviving tyrosine hydroxylase-positive neurons in the substantia nigra region and improved motor skills in response to the Ubisol-Q 10 intervention. Ubisol-Q 10 treatment halted the progression of neurodegeneration and remaining neurons were protected. The intervention begun after the completion of paraquat injections when the neurodegenerative process had already began and about 20% of TH-positive neurons were lost. Ubisol-Q 10, at 6 mg CoQ 10/kg body weight/day, was delivered as a supplement in drinking water. Neuronal death occurred over a period of 8 weeks with close to 50% reduction in the number of tyrosine hydroxylase-positive cells.
We have developed a rat model of progressive nigrostriatal degeneration by giving rats five intraperitoneal injections of paraquat (10 mg/kg/injection), once every five days.
0 kommentar(er)
